7月6日晚间，新里程（002219）(002219.SZ)披露，收到董事长林杨林家属的通知，林杨林被太原市小 店区监察委员会实施留置并立案调查。 7月7日，在发布公告披露林杨林被立案调查一事后，新里程回复了该问题："相关内容请查阅公司公 告"。 新里程称，已确认林杨林近期无法履职，所涉事项与公司无关。截至公告日，新里程未被要求协助调 查。 公开资料显示，林杨林生于1981年，毕业于对外经济贸易大学，曾任北大医疗产业基金管理有限公司 CEO。 新里程2024年年报显示，营收为38亿元，净利润为1.15亿元。林杨林于2021年3月起任董事长，2024年 度从新里程获得的薪酬为3.68万元，期末持股数为2600万股。 据新里程4月29日披露的2024年年报，审议该年报的董事会会议由新里程副董事长张延苓主持，林杨林 因个人原因未出席。 有投资者于6月9日在互动易平台提问："一把手林杨林近期从机构调研到股东大会，一直长时间未露 面，是什么原因？是否还在正常履职？" 在林杨林无法履职期间，新里程半数以上董事共同推举董事许铭桂代履行董事长职责。 新里程提到，其拥有完善的治理及内部控制机制，已对相关事项做了妥善安排。目前，其 ...

Core Viewpoint - The chairman of New Mileage, Lin Yanglin, is under investigation by the Taiyuan Municipal Xiaodian District Supervisory Committee, which has led to his inability to perform his duties. The company stated that the matter is unrelated to its operations and has not been asked to assist in the investigation [1]. Group 1: Company Operations - New Mileage's main business segments include medical services and traditional Chinese medicine, with medical services accounting for approximately 80% of its revenue [2]. - In 2024, New Mileage reported a revenue of 3.799 billion yuan and a net profit attributable to shareholders of 115 million yuan [1]. - The company operates six regional medical centers across various provinces and has a total of 24 hospitals, including three tertiary hospitals and 14 secondary or higher-level hospitals [2]. Group 2: Corporate Structure and History - New Mileage's pharmaceutical business is primarily centered around the "Duyiwei" brand of traditional Chinese medicine, which contributes about 20% to its revenue [4]. - The company was formerly known as Hengkang Medical and became controlled by Beijing New Mileage Health Industry Group in 2022 [4]. - New Mileage Group manages over 40 hospitals across nearly 20 provinces, with a total bed capacity of 30,000, ranking among the top three in the country [4]. Group 3: Financial and Regulatory Issues - On June 20, Lin Yanglin and the CFO Liu Jun were subjected to regulatory discussions by the Gansu Securities Regulatory Bureau due to non-compliance with accounting standards related to stock incentive plans and construction project accounting [6]. - The financial discrepancies have led to inaccurate disclosures in the consolidated balance sheets for the fiscal years 2023 and the first three quarters of 2024, violating the regulations on information disclosure for listed companies [6].

Group 1 - Lin Yanglin, the chairman of Xinlicheng, has been placed under detention and is under investigation, which may impact investor confidence despite the company stating the matter is unrelated to its operations [1] - Weiming Pharmaceutical's stock will be suspended for one day due to its trial progress not meeting expectations and its subsidiary's inability to resume normal operations within three months, affecting performance expectations [2] - Tengsheng Bo Pharmaceutical has signed a licensing agreement with Health Yuan Group for the exclusive rights to research, develop, and commercialize BRII-693 in China, providing cash flow and enhancing market expectations [3] Group 2 - China Resources Double Crane announced a cash dividend of 3.71 yuan per 10 shares despite a decline in revenue and net profit, indicating strong cash flow and commitment to shareholders [4] - InnoTech's subsidiary has obtained long-term product certification for a flu detection kit, which is expected to enhance market competitiveness and potentially increase revenue [5]

Core Viewpoint - The chairman of New Mileage, Lin Yanglin, is under investigation, but the company asserts that the matter is unrelated to its operations and does not expect significant adverse effects on its business [2][4]. Group 1: Investigation and Management Changes - On July 6, New Mileage announced that its chairman Lin Yanglin was placed under investigation by the Taiyuan Municipal Supervision Committee, which has resulted in his inability to perform his duties [2]. - The company has appointed director Xu Minggui to temporarily fulfill the chairman's responsibilities, while other executives continue their roles normally [2]. - Lin Yanglin has been the chairman since March 2021, following the company's bankruptcy restructuring [4]. Group 2: Financial and Operational Overview - As of the end of 2024, Lin Yanglin holds 26 million shares of New Mileage, all of which are restricted stock [3]. - In 2024, New Mileage reported revenue of 3.8 billion yuan, a year-on-year decline of 2.95%, while net profit reached 115 million yuan, a significant increase of 296.13% [6]. - The company's core business focuses on medical services and pharmaceutical industry, with medical services accounting for nearly 80% of total revenue in 2024 [4][6]. Group 3: Business Strategy - New Mileage is advancing a regional medical center strategy, establishing a "1+N" innovative service model based on comprehensive hospitals and specialized branches, and a new elderly care model [5]. - The company plans to enhance its medical institutions and pharmaceutical enterprises' integration with its controlling shareholder's investment businesses, particularly focusing on the silver economy [6].

Core Viewpoint - New Mileage (002219.SZ) announced that its chairman, Lin Yanglin, is under investigation by the Taiyuan Municipal Xiaodian District Supervisory Committee, which has led to his inability to perform his duties, although the matter is unrelated to the company [1][3] Company Governance and Management - The company has appointed director Xu Minggui to act as chairman during Lin Yanglin's absence, as per the company's articles of association [1] - New Mileage emphasizes its robust governance and internal control mechanisms, stating that other board members and senior management are functioning normally, and the company's operations remain unaffected [3] Business Strategy and Performance - Lin Yanglin has been instrumental in proposing a "comprehensive hospital + specialized branch" chain model to strengthen regional medical center layouts, with 24 hospitals established across six major regions by 2024 [2][4] - The company reported a revenue of 796 million yuan in Q1 2025, a year-on-year decline of 16.49%, and a net profit of 25.65 million yuan, down 9.35% year-on-year [3] - New Mileage's net profit saw a significant drop of 80.29% in 2023, followed by a nearly 300% increase in 2024, indicating substantial performance volatility [3] Company Background - New Mileage, originally known as Hengkang Medical Group, was listed on the A-share market in March 2008 and has transitioned from a traditional Chinese medicine manufacturer to a comprehensive healthcare group [3][4] - The company currently operates three tertiary hospitals and 14 secondary hospitals, with nearly 10,000 beds across its facilities [4]

Group 1: Hospital Upgrade and Financial Impact - Upgrading from a secondary to a tertiary hospital will increase general medical service charges by approximately 10% and surgical and examination fees by an average of 15% [3] - The estimated annual revenue increase from the upgrade is over 20 million CNY, with a cash flow increase of about 40 million CNY [4] - The reimbursement threshold for resident insurance will rise from 600 CNY to 900 CNY, and for employee insurance from 400 CNY to 600 CNY, leading to a decrease in reimbursement ratios by 5% for outpatient services and 4-7% for inpatient services [3][4] Group 2: Competitive Advantages and Service Capabilities - The hospital is the only tertiary comprehensive hospital in Siyang County, with a leading position in scale, talent, and technology [6] - It has 14 municipal clinical key specialties and 32 county-level clinical key specialties, including a national-level trauma center and stroke center [7] - The hospital has a high recognition rate among the public and employs a significant proportion of senior healthcare professionals in the county [6] Group 3: Future Development Plans - The East Hospital District is focused on oncology, rehabilitation, chronic disease management, and integrated medical care, with plans to establish a cancer treatment center [8] - Future developments will include specialized centers for emergency medicine, integrated lung cancer treatment, and metabolic disease management [8] - The hospital aims to meet the healthcare needs of the aging population and children by developing standardized specialty services [8] Group 4: Financial Structure and Cost Management - The hospital's drug cost ratio is approximately 36%, which is lower than the average for similar hospitals, with effective income accounting for 64% of total revenue [9] - The company plans to enhance hospital performance through service level improvements, optimizing disease structures, and increasing non-insured income [10] - Collaboration with insurance companies aims to increase the proportion of commercial insurance in hospital revenue [11][12]

新里程健康科技集团股份有限公司 证券简称：新里程 证券代码：002219 公告编号：2025-041 新里程健康科技集团股份有限公司 关于重大事项的公告 新里程健康科技集团股份有限公司（以下简称"公司"）收到公司董事长林 杨林先生家属的通知，公司董事长林杨林先生被太原市小店区监察委员会实施留 置并立案调查。公司确认董事长林杨林先生近期无法履职，所涉事项与公司无关。 截至本公告日，公司未被要求协助调查。 根据《公司章程》第一百一十六条的规定，公司半数以上董事共同推举董事 许铭桂先生在董事长林杨林先生无法履职期间代为履行公司董事长职责。公司拥 有完善的治理及内部控制机制，已对相关事项做了妥善安排。目前，其他董事、 监事、高级管理人员均正常履职，公司及子公司生产经营情况一切正常，本事项 预计不会对公司生产经营造成实质性重大不利影响。 截至本公告日，公司尚未知悉本事项的进展及明确结论，公司将持续关注上 述事项的后续情况，并严格按照有关法律、法规的规定和要求，及时履行信息披 露义务。敬请广大投资者理性投资，注意投资风险。 特此公告。 新里程健康科技集团股份有限公司 董 事 会 二〇二五年七月四日 1 本公司及董事会全体 ...

Company Overview - New Mile Health Technology Group Co., Ltd. focuses on medical services and pharmaceutical industry, with a primary product line that includes medicines and medical products [1] - The company has over 20 years of experience in drug production, establishing a series of traditional Chinese medicine centered around the "Duyiwei" brand, which is recognized in the 2020 edition of the "Chinese Pharmacopoeia" [1] Financial Performance - For Q1 2025, the company reported a revenue of 796 million yuan, a year-on-year decrease of 16.49%, and a net profit of 25.65 million yuan, down 9.35% year-on-year, with a gross margin of 27.96% [1] - The current stock price is 2.17 yuan, reflecting a decline of 1.36%, with a rolling price-to-earnings (PE) ratio of 65.56 times [1] Market Position - The average PE ratio for the medical services industry is 41.66 times, with a median of 43.26 times, positioning New Mile at 34th place within the industry [2] - The company's total market capitalization is 7.351 billion yuan [2] Shareholder Information - As of June 10, 2025, New Mile has 64,494 shareholders, an increase of 419 since the last report, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]

Core Insights - HomeFacialPro (hfp) has announced actress Liu Tao as its new spokesperson, promoting the theme "Gentle, Yet Powerful" to highlight the effectiveness of its fruit acid skincare products [1][2] - The collaboration aims to resonate with hfp's brand philosophy of "Let Ingredients Touch the Skin," emphasizing the importance of effective ingredients in skincare [2][4] Brand and Product Strategy - hfp focuses on addressing skincare issues such as excessive oil secretion and dull skin by utilizing fruit acid ingredients, specifically through its fruit acid essence water product [3][4] - The fruit acid essence water features a three-generation fruit acid formula that targets different skin layers, effectively unclogging pores and improving skin conditions like blackheads and acne [3] - The product includes innovative ingredients like bifida ferment and centella asiatica extract, ensuring a gentle yet effective skincare experience with a 90% repair essence base [3] Market Position and Performance - hfp has established a diverse product matrix, including various skincare items from basic lotions to advanced serums, accumulating over 30 million users [4] - The brand has been recognized as the top seller in the fruit acid skincare e-commerce market in China for three consecutive years, solidifying its position as the leading fruit acid facial care brand [4][5] - hfp's success is attributed to its deep understanding of user needs and strong research capabilities, including a partnership with Shanghai Jiao Tong University for innovative fruit acid research [4][6]

本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误导性陈述或者重大遗漏。 名称：康县独一味药材种植开发有限公司 一、担保情况概述 近日，新里程健康科技集团股份有限公司（以下简称"新里程"或"公司"）全资子公司康县独一味生物制 药有限公司（以下简称"独一味制药"）与兰州银行股份有限公司陇南武都支行（以下简称"兰州银行武 都支行"）分别签署了《最高额连带责任保证合同》，独一味制药分别为康县独一味药材种植开发有限 公司（以下简称"独一味种植"）、甘肃佛仁制药科技有限公司（以下简称"佛仁制药"）向兰州银行武都 支行申请最高授信额度提供连带责任保证，担保额度分别为人民币1,000万元及1,450万元。 二、担保审议情况 上述担保为全资子公司对公司合并报表范围内的子公司及二级控股子公司提供担保，均已履行了内部决 策程序，佛仁制药其他股东曹明月同时提供了相应的担保。根据《深圳证券交易所上市公司自律监管指 引第1号一一主板上市公司规范运作》的相关规定，无需提交公司董事会和股东大会审议。 三、被担保方基本情况 1、基本情况 成立日期：2011年11月8日 注册地点：甘肃省陇南市康县王坝独一味工业园区 法定代表 ...